QARS — Glutaminyl-tRNA Synthetase

QARS — Glutaminyl-tRNA Synthetase

<div class="infobox infobox-gene">
| Gene | |
|---|---|
| Symbol | QARS |
| Full Name | Glutaminyl-tRNA Synthetase |
| Chromosome | 3p21.31 |
| NCBI Gene ID | [5859](https://www.ncbi.nlm.nih.gov/gene/5859) |
| OMIM | [613727](https://www.omim.org/entry/613727) |
| UniProt | [P47820](https://www.uniprot.org/uniprotkb/P47820/entry) |
| Ensembl | [ENSG00000172046](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172046) |
</div>

Overview

QARS (Glutaminyl-tRNA Synthetase) encodes a member of the class I tRNA synthetase family that catalyzes the ATP-dependent attachment of L-glutamine to the 3' end of tRNA^Gln. This essential enzymatic function is critical for accurate translation of the genetic code during protein synthesis. QARS deficiency is a rare autosomal recessive disorder caused by biallelic pathogenic variants, characterized by progressive cerebellar atrophy, microcephaly, seizures, and profound developmental delay.[@zhang2016] Recent research has expanded our understanding of QARS function beyond translation to include roles in stress granule formation, RNA metabolism, and potential implications for age-related neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease.[@tavakkoli2020]

Gene Structure and Evolution

QARS — Glutaminyl-tRNA Synthetase

<div class="infobox infobox-gene">
| Gene | |
|---|---|
| Symbol | QARS |
| Full Name | Glutaminyl-tRNA Synthetase |
| Chromosome | 3p21.31 |
| NCBI Gene ID | [5859](https://www.ncbi.nlm.nih.gov/gene/5859) |
| OMIM | [613727](https://www.omim.org/entry/613727) |
| UniProt | [P47820](https://www.uniprot.org/uniprotkb/P47820/entry) |
| Ensembl | [ENSG00000172046](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172046) |
</div>

Overview

QARS (Glutaminyl-tRNA Synthetase) encodes a member of the class I tRNA synthetase family that catalyzes the ATP-dependent attachment of L-glutamine to the 3' end of tRNA^Gln. This essential enzymatic function is critical for accurate translation of the genetic code during protein synthesis. QARS deficiency is a rare autosomal recessive disorder caused by biallelic pathogenic variants, characterized by progressive cerebellar atrophy, microcephaly, seizures, and profound developmental delay.[@zhang2016] Recent research has expanded our understanding of QARS function beyond translation to include roles in stress granule formation, RNA metabolism, and potential implications for age-related neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease.[@tavakkoli2020]

Gene Structure and Evolution

The QARS gene spans approximately 34.5 kb on the reverse strand of chromosome 3p21.31 and consists of 26 exons encoding a 582-amino acid protein with a molecular weight of approximately 64 kDa. The protein possesses the characteristic class I tRNA synthetase signature motifs: the HIGH domain (positions 50-53), the KMSKS domain (positions 230-234), and a C-terminal domain involved in tRNA recognition and binding. Phylogenetic analysis reveals that QARS is highly conserved across eukaryotes, with orthologs identified in yeast (GlnRS), Drosophila, zebrafish, and mammals, reflecting its essential role in cellular function.

The genomic organization of QARS includes multiple alternative splicing variants, with the major transcript encoding the full-length cytoplasmic enzyme. Notably, a mitochondrial glutaminyl-tRNA synthetase is encoded by a separate gene (QARS2), highlighting the distinct tRNA charging requirements for cytoplasmic and mitochondrial translation. This separation ensures proper translational regulation in each cellular compartment, with QARS2 mutations causing a distinct mitochondrial disease phenotype characterized by combined oxidative phosphorylation defects and cardiomyopathy.

Protein Structure and Function

Catalytic Mechanism

QARS catalyzes the aminoacylation reaction: L-glutamine + ATP + tRNA^Gln → L-glutaminyl-tRNA^Gln + AMP + PPi. This two-step process involves formation of a glutaminyl-adenylate intermediate in the active site, followed by transfer of the activated glutamine to the 3' CCA terminus of tRNA^Gln. The enzyme exhibits high specificity for glutamine and its cognate tRNA, with discriminin domains that prevent misacylation of tRNA^Gln with glutamate or other amino acids. The KMSKS domain undergoes significant conformational changes during catalysis, transitioning from an open conformation facilitating tRNA binding to a closed conformation stabilizing the transition state.

Non-Canonical Functions

Beyond its canonical role in translation, QARS has been implicated in several non-canonical cellular functions that may be relevant to neurodegeneration:

Stress Granule Formation: During cellular stress, QARS localizes to stress granules, membrane-less organelles that sequester translationally stalled mRNAs and associated proteins. QARS interacts with G3BP1 (Ras-GAP SH3 domain-binding protein 1), a central organizer of stress granules, suggesting roles in translational control and stress response pathways. Dysregulation of stress granule dynamics has been linked to ALS, FTD, and other neurodegenerative disorders.

RNA Metabolism: QARS associates with various RNA-binding proteins and may participate in RNA processing, localization, and stability. This function is supported by proteomic studies identifying QARS in complexes with RNA helicases and splicing factors.

Cellular Signaling: There is emerging evidence that QARS may interact with signaling pathways relevant to neuronal survival, including the mTOR and AMPK pathways that integrate nutritional and stress signals.

Expression Pattern

QARS exhibits ubiquitous expression across tissues, with highest levels in tissues with high protein synthetic demands including skeletal muscle, heart, and brain. Within the central nervous system, QARS is expressed in both neurons and glia, with particular abundance in cerebellar Purkinje cells, hippocampal neurons, and cortical pyramidal neurons. This neuronal expression pattern correlates with the vulnerability of these cell types in QARS deficiency, where cerebellar atrophy and cortical involvement are hallmark features.

Expression studies in human brain show that QARS expression is relatively stable across development but may be modulated by neuronal activity and stress conditions. Single-cell RNA-seq datasets reveal moderate expression in excitatory neurons, inhibitory neurons, and astrocytes, with lower expression in microglia and oligodendrocytes.

Disease Associations

QARS Deficiency (OMIM #615760)

QARS deficiency is an autosomal recessive disorder first described in 2016 by Zhang et al., characterized by a distinctive clinical phenotype and progressive neurodegeneration. The disease typically presents in infancy or early childhood with the following core features:

Progressive Cerebellar Ataxia: The most prominent and progressive feature, manifesting as truncal ataxia, limb dysmetria, and gait instability. MRI typically reveals progressive cerebellar atrophy, particularly involving the cerebellar vermis and hemispheres. The atrophy progresses over years, leading to severe motor impairment.

Microcephaly: Present in most patients, either at birth (congenital microcephaly) or developing postnatally (acquired microcephaly). The mechanism involves impaired neuronal proliferation and migration during brain development.

Seizures: Highly prevalent, with various seizure types including infantile spasms, generalized tonic-clonic seizures, and focal seizures. Epilepsy is often refractory to standard anti-seizure medications.

Developmental Delay/Intellectual Disability: Profound global developmental delay is present, with delays in motor milestones, language acquisition, and cognitive development. Most patients achieve limited developmental milestones.

Additional Features: Some patients exhibit dysmorphic facial features, spasticity, peripheral neuropathy, and visual impairment. The phenotypic spectrum has expanded to include milder presentations with later onset and slower progression.

Amyotrophic Lateral Sclerosis (ALS)

While QARS is not a common ALS gene, rare variants have been reported in ALS patients, suggesting potential roles in motor neuron disease pathogenesis. The connection may relate to QARS function in stress granule dynamics and translational control, both processes disrupted in ALS. Studies have identified QARS variants in patients with atypical ALS presentations, including those with cerebellar involvement reminiscent of QARS deficiency.

Alzheimer's Disease and Parkinson's Disease

Indirect evidence suggests potential roles for QARS in age-related neurodegenerative diseases. Changes in tRNA charging efficiency and aminoacyl-tRNA synthetase activity have been reported in AD and PD brain tissue. Given the essential nature of these enzymes in protein synthesis, age-related decline in QARS function could contribute to proteostatic dysfunction, a hallmark of neurodegeneration. Furthermore, the accumulation of stress granules containing QARS has been observed in various neurodegenerative disease models.

Molecular Pathogenesis

The pathogenesis of QARS deficiency involves multiple interconnected mechanisms:

Impaired Translational Fidelity: Loss of QARS function leads to reduced glutaminyl-tRNA^Gln availability, causing ribosomal stalling at CAG (glutamine) codons and reduced translational efficiency for glutamine-rich proteins. This is particularly problematic for proteins with long stretches of glutamine residues, including many transcription factors and signaling proteins.

Mitochondrial Dysfunction: Secondary mitochondrial dysfunction has been documented in patient cells and models, with reduced complex I activity and ATP production. This may result from impaired translation of mitochondrial proteins or indirect effects on mitochondrial biogenesis.

Neuronal Vulnerability: Cerebellar Purkinje cells and cortical neurons exhibit particular vulnerability to QARS deficiency, possibly due to their high translational demands and the specific proteins synthesized in these cell types. The cerebellum's role in motor coordination explains the prominent ataxia.

ER Stress and Unfolded Protein Response: Recent studies suggest that QARS deficiency may induce endoplasmic reticulum stress and activate the unfolded protein response (UPR), contributing to cellular dysfunction and death.

Stress Granule Dysregulation: Impaired stress granule dynamics may lead to aberrant stress response and reduced cellular resilience to additional insults.

Diagnosis and Testing

Genetic Testing

Diagnosis relies on molecular genetic testing, typically beginning with gene panel analysis for hereditary ataxias or whole exome sequencing. Identification of biallelic pathogenic variants in QARS confirms the diagnosis. Over 40 pathogenic variants have been described, including missense variants (most common), nonsense variants, splice site variants, and small deletions. Genotype-phenotype correlations suggest that missense variants in the catalytic domain are associated with more severe phenotypes.

Biochemical Testing

Laboratory findings may include elevated lactate in cerebrospinal fluid (CSF), indicating mitochondrial dysfunction. Fibroblast studies show reduced QARS enzymatic activity and impaired protein synthesis rates. MRI demonstrates progressive cerebellar atrophy, often with concomitant cerebral volume loss.

Differential Diagnosis

QARS deficiency must be distinguished from other causes of progressive cerebellar ataxia with microcephaly, including:

• Other aminoacyl-tRNA synthetase deficiencies (e.g., DARS2, RARS2, EARS2)
• Mitochondrial disorders
• Congenital disorders of glycosylation
• DNA repair disorders

Management and Treatment

Current Management

There is currently no disease-modifying treatment for QARS deficiency. Management is supportive and multidisciplinary:

Seizure Control: Antiepileptic medications are prescribed based on seizure type, though epilepsy is often refractory. Ketogenic diet may provide benefit in some patients.

Physical and Occupational Therapy: Essential for maintaining mobility, preventing contractures, and maximizing functional abilities. Assistive devices including walkers and wheelchairs are often required.

Speech Therapy: For patients with dysarthria and swallowing difficulties.

Monitoring: Regular neurological evaluations, MRI scans to track atrophy progression, and assessment of developmental progress.

Therapeutic Approaches

Several therapeutic strategies are under investigation:

Gene Therapy: Adeno-associated virus (AAV)-mediated gene delivery is being explored to restore QARS expression. Challenges include delivering across the blood-brain barrier and achieving sufficient expression in target neurons.

Enzyme Replacement: While conceptually straightforward, delivery of functional QARS protein faces challenges with blood-brain barrier penetration and intracellular trafficking to the cytoplasm.

Small Molecule Approaches: Compounds that enhance translation fidelity, reduce ER stress, or improve mitochondrial function are being screened.

Antisense Oligonucleotides: ASOs targeting aberrant splice variants or nonsense-mediated decay are being developed.

Animal Models

Mouse models of QARS deficiency have been generated and reveal phenotype consistency with human disease. Complete knockout of Qars is embryonic lethal in mice, demonstrating its essential nature. Heterozygous mice are apparently normal, while conditional knockout in neurons leads to progressive cerebellar atrophy, motor deficits, and premature death. These models replicate key features of human QARS deficiency and provide platforms for therapeutic testing.

Zebrafish models demonstrate cerebellar degeneration and motor abnormalities following qars knockdown, offering advantages for high-throughput drug screening.

Research Directions

Current research priorities include:

Key Publications

See Also

• [Genes Index](/genes)
• [Proteins Index](/proteins)
• [Aminoacyl-tRNA Synthetases](/mechanisms/aminoacyl-trna-synthetases-neurodegeneration)
• [Cerebellar Ataxias](/diseases/progressive-cerebellar-ataxia)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules-in-neurodegeneration)
• [Translation Dysregulation](/mechanisms/translation-dysregulation-neurodegeneration)

References